Investors look ahead to 2020 following briefings from pharma chiefs at Jefferies London conferenceThe great and the good of pharma and biotech descended on London to give investors updates on how Share XInvestors look ahead to 2020 following briefings from pharma chiefs at Jefferies London conferencehttps://pharmaphorum.com/views-and-analysis/investors-look-ahead-to/
Novartis eyes $5bn The Medicines Company acquisition – reportsNovartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for Share XNovartis eyes $5bn The Medicines Company acquisition – reportshttps://pharmaphorum.com/news/novartis-eyes-5bn-the-medicines-company-acquisition-reports/
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalsThe EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’ Share XNovartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalshttps://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
FDA slaps hold on Zolgensma trials as animal data raises safety questionThe FDA has placed a partial clinical hold on Novartis’ recently-approved gene therapy Zolgensma for spinal muscular atrophy Share XFDA slaps hold on Zolgensma trials as animal data raises safety questionhttps://pharmaphorum.com/news/fda-slaps-hold-on-zolgensma-trials-as-animal-data-raises-safety-question/
Novartis takes $80M punt on early-stage NASH drug from PliantNovartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline via an $80 million licensing deal Share XNovartis takes $80M punt on early-stage NASH drug from Plianthttps://pharmaphorum.com/news/novartis-takes-80m-punt-on-early-stage-nash-drug-from-pliant/
Zolgensma hits the ground running, says NovartisNovartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that Share XZolgensma hits the ground running, says Novartishttps://pharmaphorum.com/news/zolgensma-hits-the-ground-running-says-novartis/
Sandoz says ‘no’ to Pear Therapeutics’ digital apps, handing back rightsNovartis has made no secret of its desire to become a leader in digital therapeutics (DTx), but that Share XSandoz says ‘no’ to Pear Therapeutics’ digital apps, handing back rightshttps://pharmaphorum.com/news/sandoz-says-no-to-pear-therapeutics-digital-app-handing-back-rights/
Novartis’ new eye drug undercuts Bayer’s rival with fewer injectionsThe FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s Share XNovartis’ new eye drug undercuts Bayer’s rival with fewer injectionshttps://pharmaphorum.com/news/novartis-new-eye-drug-undercuts-bayers-rival-with-less-frequent-dosing/
